Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00821002 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)
A Phase 2 study, sponsored by Mati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00821002 is a Phase 2 study that has completed, run by Mati Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT00821002, a Phase 2 study, has completed, sponsored by Mati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The study objective is to compare IOP and safety outcomes based on plug placement (upper or lower puncta).
Interventions
- DRUG Latanoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00821002
The ClinicalTrials.gov registry entry for NCT00821002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mati Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Latanoprost is the first listed.
NCT00821002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00821002 about?
NCT00821002 is a clinical study titled "A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)". The study objective is to compare IOP and safety outcomes based on plug placement (upper or lower puncta).
What is the current status of trial NCT00821002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2009-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00821002?
The interventions under investigation include: Latanoprost (DRUG).
Who is sponsoring clinical trial NCT00821002?
This trial is sponsored by Mati Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.